北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 北京大学肝病研究所  > 期刊论文
学科主题: 临床医学
题名:
Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus
作者: Wang, Ye; Rao, Hui-Ying; Xie, Xing-Wang; Wei, Lai
关键词: Antiviral Resistance ; Direct Antiviral Agents ; Hepatitis C Virus
刊名: CHINESE MEDICAL JOURNAL
发表日期: 2015-10-05
DOI: 10.4103/0366-6999.166038
卷: 128, 期:19, 页:2625-2631
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Medicine, General & Internal
研究领域[WOS]: General & Internal Medicine
关键词[WOS]: NS3 PROTEASE INHIBITORS ; FIXED-DOSE COMBINATION ; INTERFERON-ALPHA 2A ; PEGYLATED INTERFERON ; PLUS RIBAVIRIN ; NS5A INHIBITOR ; OPEN-LABEL ; VIROLOGICAL ESCAPE ; DRUG-RESISTANCE ; PHASE-2 TRIAL
英文摘要:

Background: It has been reported that several baseline polymorphisms of direct-acting antivirals (DAAs) agents resistance-associated variants (RAVs) would affect the treatment outcomes of patients chronically infected with hepatitis C virus (CHC). The aim of this study is to investigate the prevalence of DAAs RAVs in treatment-naive GT1b CHC patients.

Methods: Direct sequencing and ultra-deep sequencing of the HCV NS3, NS5A, and NS5B gene were performed in baseline serum samples of treatment-naive patients infected with genotype 1b hepatitis C virus (HCVs).

Results: One hundred and sixty CHC patients were studied. Complete sequence information was obtained for 145 patients (NS3), 148 patients (NS5A), and 137 patients (NS5B). Treatment-failure associated variants of DAAs were detected: 56.6% (82/145) of the patients presented S122G for simeprevir (NS3 protease inhibitor); 10.1% (14/148) of the patients presented Y93H for daclatasvir and ledipasvir (NS5A protein inhibitors); 94.2% (129/137) of the patients presented C316N for sofosbuvir (NS5B polymerase inhibitor). Nearly, all of the DAAs RAVs detected by ultra-deep sequencing could be detected by direct sequencing.

Conclusions: The majority of genotype 1b CHC patients in China present a virus population carrying HCV DAAs RAVs. Pretreatment sequencing of HCV genome might need to be performed when patients infected with GT1b HCV receiving DAAs-containing regimens in China. Population sequencing would be quite quantified for the work.

语种: 英语
所属项目编号: 2008ZX10002-013 ; 2008ZX10002-012 ; 2012ZX10002003
项目资助者: China National Science and Technology Major Project for Infectious Diseases Control
WOS记录号: WOS:000362853100012
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/64738
Appears in Collections:北京大学第二临床医学院_北京大学肝病研究所_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Peoples Hosp, Inst Hepatol, Beijing Key Lab Hepatitis & Immunotherapy Liver D, Beijing 100044, Peoples R China

Recommended Citation:
Wang, Ye,Rao, Hui-Ying,Xie, Xing-Wang,et al. Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus[J]. CHINESE MEDICAL JOURNAL,2015,128(19):2625-2631.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Wang, Ye]'s Articles
[Rao, Hui-Ying]'s Articles
[Xie, Xing-Wang]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Wang, Ye]‘s Articles
[Rao, Hui-Ying]‘s Articles
[Xie, Xing-Wang]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace